(Reuters) - German drugmaker Merck KGaA agreed with Japan’s Ono Pharmaceutical to terminate a license agreement over Ono’s experimental multiple sclerosis (MS) drug ceralifimod.
Merck, the maker of MS drug Rebif, said on Tuesday the project did “not meet Merck’s threshold for continued investment”.
Help employers find you! Check out all the jobs and post your resume.
